United Immunity enters into a Research Collaboration Agreement with AstraZeneca
07/26/2024
Portfolio News
New
United Immunity develops its proprietary active targeting pullulan lipid nanoparticle (LNP) selective to myeloid cells as its Myeloid Targeting Platform.
Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases
02/29/2024
Portfolio News
Proceeds to be used to complete clinical proof-of-concept trial for lead candidate, RNDP-001, for the treatment of Parkinson’s disease.
Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B
12/05/2023
Portfolio News
Data shows deep repression of HBV both in primary cells and ‘gold standard’
humanized mouse model